Literature DB >> 28067753

Long-term Extent Change of Pediatric-Onset Ulcerative Colitis.

Firas Rinawi1, Amit Assa1,2, Corina Hartman1,2, Yael Mozer Glassberg1,2, Vered Nachmias Friedler1, Yoram Rosenbach1, Ari Silbermintz1, Noam Zevit1,2, Raanan Shamir1,2.   

Abstract

BACKGROUND: Data describing extent change (progression or regression) in pediatric-onset ulcerative colitis (UC) are scarce. GOAL: We aimed to describe extent change in pediatric-onset UC during long-term follow-up and to assess predictors of extent change. STUDY: Medical charts of pediatric-onset UC patients with at least 5-year follow-up were analyzed retrospectively. Disease extent was determined using the Paris classification. It was examined at diagnosis and during follow-up at different time points. The impact of possible predictors on extent change including age at diagnosis, gender, clinical manifestations, disease, severity indices, and different therapeutic regimens during disease course was assessed.
RESULTS: Patients (n=134, 55% males) were followed for a median duration of 13.1 (range, 5 to 28) years. Median age at diagnosis was 13.1 (range, 2 to 17.8) years. Of 134 patients, 40.5% had extensive or pancolitis, 33.5% left-sided colitis, and 26% had proctitis at diagnosis. On follow-up (n=117), 45% had unchanged disease extent, 35% experienced extent progression, whereas 20% experienced regression of disease extent. The multivariate Cox models demonstrated that among children with left-sided disease at diagnosis, presence of extraintestinal manifestations (hazard ratio, 5.19; P=0.022), and higher pediatric UC activity index (hazard ratio, 8.77; P=0.008) were associated with extent progression to extensive disease. Predictors of extent regression have not been identified.
CONCLUSIONS: Disease extent changes significantly over time in pediatric-onset UC. In our cohort, presence of extraintestinal manifestation and higher pediatric UC activity index score at diagnosis were associated with progression from limited to extensive disease during follow-up.

Entities:  

Mesh:

Year:  2018        PMID: 28067753     DOI: 10.1097/MCG.0000000000000741

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis.

Authors:  Suresh Venkateswaran; Jarod Prince; David J Cutler; Urko M Marigorta; David T Okou; Sampath Prahalad; David Mack; Brendan Boyle; Thomas Walters; Anne Griffiths; Cary G Sauer; Neal LeLeiko; David Keljo; James Markowitz; Susan S Baker; Joel Rosh; Marian Pfefferkorn; Melvin B Heyman; Ashish Patel; Anthony Otley; Robert Baldassano; Joshua Noe; Paul Rufo; Maria Oliva-Hemker; Sonia Davis; Michael E Zwick; Greg Gibson; Lee A Denson; Jeffrey Hyams; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2018-03-19       Impact factor: 5.325

2.  Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.

Authors:  Gyorgy Kovacs; Nora Sipeki; Boglarka Suga; Tamas Tornai; Kai Fechner; Gary L Norman; Zakera Shums; Peter Antal-Szalmas; Maria Papp
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

3.  Severe Disease Activity Based on the Paris Classification Is Associated with the Development of Extraintestinal Manifestations in Korean Children and Adolescents with Ulcerative Colitis.

Authors:  Hyo-Jeong Jang; Hyo Rim Suh; Sujin Choi; Suk Jin Hong; Seung-Man Cho; Kwang-Hae Choi; Byung-Ho Choe; Ben Kang
Journal:  J Korean Med Sci       Date:  2021-11-15       Impact factor: 2.153

4.  Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea.

Authors:  Jooyoung Jang; Sung Hee Lee; In Sook Jeong; Jinmin Cho; Hyun Jin Kim; Seak Hee Oh; Dae Yeon Kim; Ho-Su Lee; Sang Hyoung Park; Byong Duk Ye; Suk-Kyun Yang; Kyung Mo Kim
Journal:  Gut Liver       Date:  2022-03-15       Impact factor: 4.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.